financetom
Business
financetom
/
Business
/
Vertex Q2 Adjusted Earnings Flat, Revenue Rises; 2025 Revenue Guidance Updated
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Vertex Q2 Adjusted Earnings Flat, Revenue Rises; 2025 Revenue Guidance Updated
Aug 6, 2025 5:15 AM

07:58 AM EDT, 08/06/2025 (MT Newswires) -- Vertex (VERX) reported Q2 adjusted earnings Wednesday of $0.15 per diluted share, unchanged from a year earlier.

Analysts surveyed by FactSet expected $0.14.

Revenue for the quarter ended June 30 was $184.6 million, up from $161.1 million a year earlier.

That result matched the average estimate of analysts polled by FactSet.

The company said it expects Q3 revenue to be between $190 million and $193 million. Analysts surveyed by FactSet expect 195.8 million.

Revenue for the current year is projected to be $750 million to $754 million, the company said. That compares with a range of $760 million to $768 million previously. Analysts polled by FactSet expect 763.4 million.

Shares of the company were down more than 2% in recent Wednesday premarket activity.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
S&P Global Ratings Previews This Week's Bank of Canada Policy Meeting
S&P Global Ratings Previews This Week's Bank of Canada Policy Meeting
Mar 11, 2025
07:35 AM EDT, 03/11/2025 (MT Newswires) -- S&P Global Ratings said it anticipates the Bank of Canada will lower interest rates by 25bps this week, bringing the rate down to 2.75%. This follows a substantial 200bps reduction in overnight rates since the Canadian central bank began its monetary policy normalization last June. The BoC is slated to release its policy...
Top Premarket Decliners
Top Premarket Decliners
Mar 11, 2025
07:58 AM EDT, 03/11/2025 (MT Newswires) -- Zymeworks ( ZYME ) shares slumped 46% pre-bell Tuesday, adding to Monday's losses. Arvinas ( ARVN ) shares retreated 41% after the company and Pfizer (PFE) said their phase 3 trial of vepdegestrant for the treatment of breast cancer failed to reach statistical significance in improvement in progression free survival in the intent-to-treat...
Tilray Medical Introduces High THC, High Terpene Genetics to German Medical Cannabis Market
Tilray Medical Introduces High THC, High Terpene Genetics to German Medical Cannabis Market
Mar 11, 2025
08:01 AM EDT, 03/11/2025 (MT Newswires) -- Tilray Medical, a division of Tilray Brands ( TLRY ), (TLRY.TO) on Tuesday said it is introducing in Germany the Tilray Craft brand, a new extension of the Tilray Medical brand. Tilray Craft is being introduced to address the needs of patients in Germany for flower-based medical cannabis with higher THC and higher...
BRIEF-Labcorp Announces Acquisition Of Select Assets Of Bioreference Health's Innovative Oncology And Related Clinical Testing Services Businesses
BRIEF-Labcorp Announces Acquisition Of Select Assets Of Bioreference Health's Innovative Oncology And Related Clinical Testing Services Businesses
Mar 11, 2025
March 11 (Reuters) - Labcorp Holdings Inc ( LH ): * LABCORP ANNOUNCES ACQUISITION OF SELECT ASSETS OF BIOREFERENCE HEALTH'S INNOVATIVE ONCOLOGY AND RELATED CLINICAL TESTING SERVICES BUSINESSES * LABCORP ( LH ): PURCHASE PRICE FOR TRANSACTION IS UP TO $225 MILLION Source text: Further company coverage: ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved